Therapy News and Research

RSS

Special public meeting to spotlight stem cell-based therapies for ALS

Local scientists, health advocates and leaders from the California Institute for Regenerative Medicine will gather in San Diego June 23 for a special public meeting to spotlight a new University of California, San Diego grant to pursue novel, fast-tracked stem cell-based therapies for amyotrophic lateral sclerosis, or Lou Gehrig's disease.

18 Jun 2010

Life Technologies announces product launches in concert with ISSCR 8th Annual Meeting

Life Technologies Corporation, a provider of innovative life science solutions, today announced activities and product launches in concert with the International Society for Stem Cell Research (ISSCR) 8th Annual Meeting that highlight the company's offerings of complete end-to-end solutions for stem cell research. Stem cell research has been shown to be a critical component of regenerative medicine; a basis for identifying drug targets and drug screening; and an important step in the development of therapies to treat a variety of diseases.

18 Jun 2010

New multimillion dollar BSL-3 laboratory complex at Nigerian National TB and Leprosy Training Center

This week, the U.S. Centers for Disease Control (CDC) Director, Dr. Tom Frieden, visited the Nigerian National TB and Leprosy Training Center (NTBLTC) to tour a multimillion dollar laboratory complex established by the Institute of Human Virology (IHV) of the University of Maryland School of Medicine in Baltimore, Maryland, and the Institute of Human Virology-Nigeria. This U.S.-Nigeria partnership was established in 2004 through funding from the CDC and the President's Emergency Plan For AIDS Relief (PEPFAR).

18 Jun 2010

Researchers evaluate dental pulp cells as optimal source of iPS cells

Defined sets of factors can reprogram human cells to induced pluripotent stem cells. However, many types of human cells are not easily accessible to minimally invasive procedures. In a paper published in the International and American Associations for Dental Research's Journal of Dental Research, lead researcher K. Tezuka and researchers N. Tamaoki, H. Aoki, T. Takeda-Kawaguchi, K. Iida, T. Kunisada and T. Shibata all from the Gifu University Graduate School of Medicine, Japan; and K. Takahashi, T. Tanaka and S. Yamanaka, all from Kyoto University, Japan, evaluate dental pulp cells as an optimal source of iPS cells, since they are easily obtained from extracted teeth and can be expanded under simple culture conditions.

18 Jun 2010

Researchers identify how obese people become salt sensitive, hypertensive

One way obese people become salt sensitive and hypertensive has been identified by Medical College of Georgia researchers.

18 Jun 2010

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its FDA-approved diabetes drugs, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection, and its investigational diabetes drug candidate BYDUREON (exenatide extended-release for injectable suspension) at the American Diabetes Association's 70th Annual Scientific Sessions being held in Orlando, FL from June 25 to June 29.

18 Jun 2010

Stem cell therapy leads to development of blood vessel, bone marrow masses

Following stem cell therapy, an adult patient experienced a new and previously unrecognized complication, which required removal of one of the kidneys, according to a case report appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The report suggests that stem cell therapy may cause patients to develop blood vessel and bone marrow masses, the long term effects of which are unknown.

18 Jun 2010

One-step surgery positively impacts patient's quality of life: Study

Restoring people's health and returning them to their daily lives as soon as possible is the goal following any surgery. When a person's ability to eat and speak is affected, as with cancer in the mouth, surgery is particularly disruptive, creating a greater challenge. A one-step surgery can remove cancerous tissue and reconstruct bone and teeth functionality immediately, positively impacting the patient's quality of life.

18 Jun 2010

DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced results from DURATION-4, the fourth in a series of studies designed to test the superiority of BYDUREON (exenatide extended-release for injectable suspension), an investigational type 2 diabetes therapy, as compared to other type 2 diabetes medications.

18 Jun 2010

Review of possible uses, limits of WB-MRI procedure

Thanks to technical progress, there are now new areas in which whole body magnetic resonance imaging can be used. In the current edition of Deutsches -rzteblatt International (Dtsch Arztebl Int 2010; 107[22]: 383-9), Gerwin Schmidt and his coauthors present a review of possible uses, together with the limits of this radiation-free diagnostic procedure.

18 Jun 2010

University of Utah makes progress against SMA with support of Families of Spinal Muscular Atrophy

18 Jun 2010

Nurse-monitored ART found to be as safe, effective as therapy monitored by doctors in South African trial

"HIV drugs can be administered as effectively by nurses as by doctors, a finding that could yield major benefits in the fight against AIDS in Africa," according to a study published online Wednesday in the Lancet, Agence France-Presse reports.

18 Jun 2010

UF administers Lumizyme for late-onset Pompe disease

The first commercially available treatment in the United States for patients with late-onset Pompe disease was administered Wednesday, June 16, at the University of Florida.

18 Jun 2010

VCU researchers discover mechanism that regulates gene expression and growth in melanoma cells

Virginia Commonwealth University researchers have discovered a mechanism by which an enzyme regulates gene expression and growth in melanoma cells, a finding that could someday lead to more effective drugs to attack cancers and make them more treatable.

18 Jun 2010

Researchers make significant headway in fight against SMA

Researchers at the University of Utah are making strides in understanding and combating a motor neuron disease known as Spinal Muscular Atrophy. The spinal muscular atrophies are a group of inherited diseases that cause progressive degeneration of motor nerves resulting in muscle weakness. The most common form of the disorder, due to the deletion of a critical gene on chromosome 5, is currently the leading cause of inherited infant and child mortality.

18 Jun 2010

NMT Medical receives preliminary results for CLOSURE I PFO/stroke and transient ischemic attack trial

NMT Medical, Inc., an advanced medical technology company that designs, develops, manufactures and markets proprietary implant technologies that allow interventional cardiologists to treat structural heart disease through minimally invasive, catheter-based procedures, today announced that it has received preliminary results for CLOSURE I, its patent foramen ovale (PFO)/stroke and transient ischemic attack (TIA) trial in the U.S.

18 Jun 2010

CLEAR study meets primary endpoint: Sorin Group

Sorin Group, a global leader in the treatment of cardiovascular diseases, announced today that the CLEAR study has met its primary endpoint.

18 Jun 2010

Maternal, infant ART drives down mother-to-child HIV transmission through breast-feeding, studies show

According to two new studies, "giving pregnant and nursing women triple antiretroviral drug therapy, or treating breast-fed infants with an antiretroviral medication, can dramatically cut transmission rates, enabling moms to both breast-feed and to protect nearly all children from infection," HealthDay News/Bloomberg Businessweek reports (Goodwin, 6/16).

18 Jun 2010

EC grants Allos Therapeutics' pralatrexate orphan medicinal product designation for CTCL treatment

Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.

18 Jun 2010

FDA approves new indication for Tasigna in treatment of rare blood cancer

The U.S. Food and Drug Administration today approved a new indication for Tasigna (nilotinib) for the treatment of a rare blood cancer when it is first diagnosed. The cancer, called Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML), is a slowly progressing blood and bone marrow disease linked to a genetic abnormality.

18 Jun 2010

Therapy News and Research

Special public meeting to spotlight stem cell-based therapies for ALS

Life Technologies announces product launches in concert with ISSCR 8th Annual Meeting

New multimillion dollar BSL-3 laboratory complex at Nigerian National TB and Leprosy Training Center

Researchers evaluate dental pulp cells as optimal source of iPS cells

Researchers identify how obese people become salt sensitive, hypertensive

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

Stem cell therapy leads to development of blood vessel, bone marrow masses

One-step surgery positively impacts patient's quality of life: Study

DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications

Review of possible uses, limits of WB-MRI procedure

University of Utah makes progress against SMA with support of Families of Spinal Muscular Atrophy

Nurse-monitored ART found to be as safe, effective as therapy monitored by doctors in South African trial

UF administers Lumizyme for late-onset Pompe disease

VCU researchers discover mechanism that regulates gene expression and growth in melanoma cells

Researchers make significant headway in fight against SMA

NMT Medical receives preliminary results for CLOSURE I PFO/stroke and transient ischemic attack trial

CLEAR study meets primary endpoint: Sorin Group

Maternal, infant ART drives down mother-to-child HIV transmission through breast-feeding, studies show

EC grants Allos Therapeutics' pralatrexate orphan medicinal product designation for CTCL treatment

FDA approves new indication for Tasigna in treatment of rare blood cancer

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News